Diagnose It Yourself: Will There Be a Home Test Kit for Alzheimer’s disease?

References

• Prince MJ , WimoA, GuerchetMM, AliGC, WuY-T, PrinaM. World Alzheimer Report 2015 - The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends.. Alzheimers Dis. Int. (ADI)Alzheimer’s Disease International, London, UK (2015).
   Google Scholar
• Alzheimer’s Disease International . World Alzheimer Report 2019: attitudes to dementia. Alzheimers Dis. Int. (ADI) London, UK (2019).
   Google Scholar
• Bekris LM , YuCE, BirdTD, TsuangDW. Review article: Genetics of Alzheimer disease. J. Geriatr. Psychiatry Neurol., 23(4), 213–227 (2010).
   PubMed Web of Science ®Google Scholar
• Corder EH , SaundersAM, StrittmatterWJet al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science, 261(5123), 921–923 (1993).
   PubMed Web of Science ®Google Scholar
• Kivipelto M , MangialascheF, NganduT. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. Nat. Rev. Neurol., 14(11), 653–666 (2018).
   PubMed Web of Science ®Google Scholar
• Hsu D , MarshallGA. Primary and secondary prevention trials in Alzheimer disease: looking back, moving forward. Curr. Alzheimer Res., 14(4), 426–440 (2017).
   PubMed Web of Science ®Google Scholar
• Brookmeyer R , JohnsonE, Ziegler-GrahamK, ArrighiHM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement., 3(3), 186–191 (2007).
   PubMed Web of Science ®Google Scholar
• Blennow K , de LeonMJ, ZetterbergH. Alzheimer’s disease. Lancet, 368, 387–403 (2006).
   PubMed Web of Science ®Google Scholar
• Villemagne VL , BurnhamS, BourgeatPet al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol., 12(4), 357–367 (2013).
   PubMed Web of Science ®Google Scholar
• Jessen F , AmariglioRE, van BoxtelMet al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement., 10(6), 844–852 (2014).
   PubMed Web of Science ®Google Scholar
• Rönnlund M , SundströmA, AdolfssonR, NilssonLG. Subjective memory impairment in older adults predicts future dementia independent of baseline memory performance: evidence from the Betula prospective cohort study. Alzheimers Dement., 11(11), 1385–1392 (2015).
   PubMed Web of Science ®Google Scholar
• Albert MS , DeKoskyST, DicksonDet al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement., 7(3), 270–279 (2011).
   PubMed Web of Science ®Google Scholar
• Daneman R , PratA. The blood–brain barrier. Cold Spring Harb. Perspect. Biol., 7(1), a020412 (2015).
   PubMed Web of Science ®Google Scholar
• Gupta S , DhandaS, SandhirR. Anatomy and physiology of blood–brain barrier. In: Brain Targeted Drug Delivery System – A Focus on Nanotechnology and Nanoparticulates. Elsevier, Amsterdam, The Netherlands, 7–31 (2019).
   Google Scholar
• Pardridge WM . CSF, blood–brain barrier, and brain drug delivery. Expert Opin. Drug Deliv., 13(7), 963–975 (2016).
   PubMed Web of Science ®Google Scholar
• Perry VH , CunninghamC, HolmesC. Systemic infections and inflammation affect chronic neurodegeneration. Nat. Rev. Immunol., 7(2), 161–167 (2007).
   PubMed Web of Science ®Google Scholar
• Heneka MT , CarsonMJ, KhouryJ Elet al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol., 14(4), 388–405 (2015).
   PubMed Web of Science ®Google Scholar
• Popp J , OikonomidiA, TautvydaitėDet al. Markers of neuroinflammation associated with Alzheimer’s disease pathology in older adults. Brain Behav. Immun., 62, 203–211 (2017).
   PubMed Web of Science ®Google Scholar
• Schipke CG , GünterO, WeinertCet al. Definition and quantification of six immune- and neuroregulatory serum proteins in healthy and demented elderly. Neurodegener. Dis. Manag., 9(4), 193–203 (2019).
   PubMed Web of Science ®Google Scholar
• Ouyang M , TuD, TongLet al. A review of biosensor technologies for blood biomarkers toward monitoring cardiovascular diseases at the point-of-care. Biosens. Bioelectron., 171, 112621 (2021).
   PubMed Web of Science ®Google Scholar
• Morris JC . Clinical Dementia Rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int. Psychogeriatrics, 9(Suppl. 1), 173–176 (1997).
   PubMedGoogle Scholar
• Morris JC , HeymanA, MohsRCet al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology, 39(9), 1159–1165 (1989).
   PubMed Web of Science ®Google Scholar
• Frölich L , PetersO, LewczukPet al. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia. Alzheimers Res. Ther., 9(1), 84 (2017).
   PubMedGoogle Scholar
• Jack CR Jr , BennettDA, BlennowKet al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement., 14(4), 535–562 (2018).
   PubMed Web of Science ®Google Scholar
• Müller EG , EdwinTH, StokkeCet al. Amyloid-β PET–correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer’s disease diagnosis in a memory clinic. PLoS ONE, 14(8), e0221365 (2019).
   PubMed Web of Science ®Google Scholar
• Brier MR , GordonB, FriedrichsenKet al. Tau and Ab imaging, CSF measures, and cognition in Alzheimer’s disease. Sci. Transl. Med., 8(338), 338ra66 (2016).
   PubMed Web of Science ®Google Scholar
• Johnson KA , FoxNC, SperlingRA, KlunkWE. Brain imaging in Alzheimer disease. Cold Spring Harb. Perspect. Med., 2(4), a006213 (2012).
   PubMed Web of Science ®Google Scholar
• Prins ND , ScheltensP. White matter hyperintensities, cognitive impairment and dementia: an update. Nat. Rev. Neurol., 11(3), 157–165 (2015).
   PubMed Web of Science ®Google Scholar
• Taphoorn MJB , KleinM. Cognitive deficits in adult patients with brain tumours. Lancet Neurol., 3(3), 159–168 (2004).
   PubMed Web of Science ®Google Scholar
• Horvath A , SzucsA, CsuklyG, SakovicsA, StefanicsG, KamondiA. EEG and ERP biomarkers of Alzheimer’s disease: a critical review. Front. Biosci. (Landmark Ed.), 23, 183–220 (2018).
   PubMed Web of Science ®Google Scholar
• Freitas Pereira MLG , von ZubenA, CamargoMZ, AprahamianI, ForlenzaOV. Eye movement analysis and cognitive processing: detecting indicators of conversion to Alzheimer’s disease. Neuropsychiatr. Dis. Treat., 10, 1273–1285 (2014).
   PubMed Web of Science ®Google Scholar
• Crivelli SM , GiovagnoniC, VisserenLet al. Sphingolipids in Alzheimer’s disease, how can we target them? Adv. Drug Deliv. Rev., 159, 214–231 (2020).
   PubMed Web of Science ®Google Scholar
• Varma VR , OommenAM, VarmaSet al. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: a targeted metabolomics study. PLoS Med., 15(1), e1002482 (2018).
   PubMed Web of Science ®Google Scholar
• Raket LL , KühnelL, SchmidtE, BlennowK, ZetterbergH, Mattsson-CarlgrenN. Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer’s disease. Alzheimers Dement. (Amst.), 12(1), e12099 (2020).
   PubMedGoogle Scholar
• Karikari TK , PascoalTA, AshtonNJet al. Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol., 19(5), 422–433 (2020).
   PubMed Web of Science ®Google Scholar
• Shen X , LiJ, WangHet al. Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer’s disease pathology and clinical progression in older adults without dementia. Alzheimers Dement. (Amst.), 12(1), e12104 (2020).
   PubMedGoogle Scholar
• Park JC , HanSH, YiDet al. Plasma tau/amyloid-β 1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer’s disease. Brain, 142(3), 771–786 (2019).
   PubMedGoogle Scholar
• Janelidze S , MattssonN, PalmqvistSet al. Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat. Med., 26(3), 379–386 (2020).
   PubMed Web of Science ®Google Scholar
• Palmqvist S , JanelidzeS, QuirozYTet al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA, 324(8), 772–781 (2020).
   PubMed Web of Science ®Google Scholar
• Rózga M , BittnerT, BatrlaR, KarlJ. Preanalytical sample handling recommendations for Alzheimer’s disease plasma biomarkers. Alzheimers Dement. (Amst.), 11, 291–300 (2019).
   PubMedGoogle Scholar
• Palmqvist S , JanelidzeS, StomrudEet al. Performance of fully automated plasma assays as screening tests for Alzheimer disease-related β-amyloid status. JAMA Neurol., 76(9), 1060–1069 (2019).
   PubMed Web of Science ®Google Scholar
• Kaneko N , NakamuraA, WashimiYet al. Novel plasma biomarker surrogating cerebral amyloid deposition. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci., 90(9), 353–364 (2014).
   PubMed Web of Science ®Google Scholar
• Nakamura A , KanekoN, VillemagneVLet al. High performance plasma amyloid-β biomarkers for Alzheimer’’s disease. Nature, 554(7691), 249–254 (2018).
   PubMed Web of Science ®Google Scholar
• Ovod V , RamseyKN, MawuenyegaKGet al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement., 13(8), 841–849 (2017).
   PubMed Web of Science ®Google Scholar
• Jia L , QiuQ, ZhangHet al. Concordance between the assessment of Aβ42, T-tau, and P-T181-tau in peripheral blood neuronal-derived exosomes and cerebrospinal fluid. Alzheimers Dement., 15, 1071–1080 (2019).
   PubMed Web of Science ®Google Scholar
• Nabers A , PernaL, LangeJet al. Amyloid blood biomarker detects Alzheimer’s disease. EMBO Mol. Med., 10, e8763 (2018).
   PubMed Web of Science ®Google Scholar
• Hampel H , CaraciF, CuelloACet al. A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer’s disease. Front. Immunol., 11, 456 (2020).
   PubMed Web of Science ®Google Scholar
• Schipke CG , MenneF, RubowS, SigleJ-P, PetersO, GrimmerT. Value of a panel of 6 serum biomarkers to differentiate between healthy controls and mild cognitive impairment due to Alzheimer disease. Alzheimer Dis. Assoc. Disord., 34(4), 318–324 (2020).
   PubMed Web of Science ®Google Scholar
• Hesse R , WahlerA, GummertPet al. Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1β. BMC Neurol., 16(1), 185 (2016).
   PubMedGoogle Scholar
• Khalil M , TeunissenCE, OttoMet al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol., 14, 577–589 (2018).
   PubMed Web of Science ®Google Scholar
• Mattsson N , AndreassonU, ZetterbergHet al. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol., 74(5), 557–566 (2017).
   PubMed Web of Science ®Google Scholar
• Mattsson N , CullenNC, AndreassonU, ZetterbergH, BlennowK. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol., 76(7), 791–799 (2019).
   PubMed Web of Science ®Google Scholar
• Yoo HS , JeonS, ChungSJet al. Olfactory dysfunction in Alzheimer’s disease– and Lewy body–related cognitive impairment. Alzheimers Dement., 14(10), 1243–1252 (2018).
   PubMed Web of Science ®Google Scholar
• Attems J , LintnerF, JellingerKA. Olfactory involvement in aging and Alzheimer’s disease: an autopsy study. J. Alzheimers Dis., 7(2), 149–157 (2005).
   PubMed Web of Science ®Google Scholar
• Arnold SE , LeeEB, MobergPJet al. Olfactory epithelium amyloid-β and paired helical filament-tau pathology in Alzheimer disease. Ann. Neurol., 67(4), 462–469 (2010).
   PubMed Web of Science ®Google Scholar
• Pellkofer H , IhlerF, WeissBGet al. Evaluation of the methoxy-X04 derivative BSC4090 for diagnosis of prodromal and early Alzheimer’s disease from bioptic olfactory mucosa. Eur. Arch. Psychiatry Clin. Neurosci., 269(8), 973–984 (2019).
   PubMed Web of Science ®Google Scholar
• Wolf OT , ConvitA, ThornE, DeLeon MJ. Salivary cortisol day profiles in elderly with mild cognitive impairment. Psychoneuroendocrinology, 27(7), 777–789 (2002).
   PubMed Web of Science ®Google Scholar
• De La Rubia Ortí JE , CastilloSS, BenllochM, RochinaMJ, ArrecheSC, García-PardoMP. Impact of the relationship of stress and the immune system in the appearance of Alzheimer’s disease. J. Alzheimers Dis., 55(3), 899–903 (2017).
   PubMed Web of Science ®Google Scholar
• Yilmaz A , GeddesT, HanBet al. Diagnostic biomarkers of Alzheimer’s disease as identified in saliva using 1H NMR-based metabolomics. J. Alzheimers Dis., 58(2), 355–359 (2017).
   PubMed Web of Science ®Google Scholar
• Tsuruoka M , HaraJ, HirayamaAet al. Capillary electrophoresis-mass spectrometry-based metabolome analysis of serum and saliva from neurodegenerative dementia patients. Electrophoresis, 34(19), 2865–2872 (2013).
   PubMed Web of Science ®Google Scholar
• Choromańska M , KlimiukA, Kostecka-SochońPet al. Antioxidant defence, oxidative stress and oxidative damage in saliva, plasma and erythrocytes of dementia patients. Can salivary AGE be a marker of dementia? Int. J. Mol. Sci., 18(10), 2205 (2017).
   PubMed Web of Science ®Google Scholar
• Su H , GornitskyM, GengG, VellyAM, ChertkowH, SchipperHM. Diurnal variations in salivary protein carbonyl levels in normal and cognitively impaired human subjects. Age (Omaha), 30(1), 1–9 (2008).
   Google Scholar
• Lee M , GuoJP, KennedyK, McgeerEG, McGeerPL. A method for diagnosing Alzheimer’s disease based on salivary amyloid-β protein 42 levels. J. Alzheimers Dis., 55(3), 1175–1182 (2017).
   PubMed Web of Science ®Google Scholar
• Bermejo-Pareja F , AntequeraD, VargasT, MolinaJA, CarroE. Saliva levels of Abeta1-42 as potential biomarker of Alzheimer’s disease: a pilot study. BMC Neurol., 10, 108 (2010).
   PubMed Web of Science ®Google Scholar
• Kim C-B , ChoiYY, SongWK, SongK-B. Antibody-based magnetic nanoparticle immunoassay for quantification of Alzheimer’s disease pathogenic factor. J. Biomed. Opt., 19(5), 051205 (2014).
   PubMed Web of Science ®Google Scholar
• Shi M , SuiYT, PeskindERet al. Salivary tau species are potential biomarkers of Alzheimer’s disease. J. Alzheimers Dis., 27(2), 299–305 (2011).
   PubMed Web of Science ®Google Scholar
• Lau HC , LeeIK, KoPWet al. Non-invasive screening for Alzheimer’s disease by sensing salivary sugar using Drosophila cells expressing gustatory receptor (Gr5a) immobilized on an extended gate ion-sensitive field-effect transistor (EG-ISFET) biosensor. PLoS ONE, 10(2), e0117810 (2015).
   PubMed Web of Science ®Google Scholar
• Ashton NJ , IdeM, SchöllMet al. No association of salivary total tau concentration with Alzheimer’s disease. Neurobiol. Aging, 70, 125–127 (2018).
   PubMed Web of Science ®Google Scholar
• Fenech M , ThomasP. Telomere length in white blood cells, buccal cells and brain tissue and its variation with aging and Alzheimer’s disease. Alzheimers Dement., 6(4), S511 (2010).
   Google Scholar
• Thomas P , O’Callaghan NJ, FenechM. Telomere length in white blood cells, buccal cells and brain tissue and its variation with ageing and Alzheimer’s disease. Mech. Ageing Dev., 129(4), 183–190 (2008).
   PubMed Web of Science ®Google Scholar
• Mathur S , GlogowskaA, McAvoyEet al. Three-dimensional quantitative imaging of telomeres in buccal cells identifies mild, moderate, and severe Alzheimer’s disease patients. J. Alzheimers Dis., 39(1), 35–48 (2014).
   PubMed Web of Science ®Google Scholar
• Garcia A , MathurS, KalawMCet al. Quantitative 3D telomeric imaging of buccal cells reveals Alzheimer’s disease-specific signatures. J. Alzheimers Dis., 58(1), 139–145 (2017).
   PubMed Web of Science ®Google Scholar
• François M , LeifertW, HeckerJet al. Altered cytological parameters in buccal cells from individuals with mild cognitive impairment and Alzheimer’s disease. Cytom. Part A, 85(8), 698–708 (2014).
   PubMedGoogle Scholar
• François M , FenechMF, ThomasPet al. High content, multi-parameter analyses in buccal cells to identify Alzheimer’s disease. Curr. Alzheimer Res., 13(7), 787–799 (2016).
   PubMed Web of Science ®Google Scholar
• Garcia A , HuangD, RigholtAet al. Super-resolution structure of DNA significantly differs in buccal cells of controls and Alzheimer’s patients. J. Cell. Physiol., 232(9), 2387–2395 (2017).
   PubMed Web of Science ®Google Scholar
• Leifert WR , FerdoushTuli J, FrancoisMet al. Buccal cell cytokeratin 14 identifies mild cognitive impairment and Alzheimer’s disease in the AIBL study of aging. Curr. Alzheimer Res., 12(3), 233–241 (2015).
   PubMed Web of Science ®Google Scholar
• Hattori H , MatsumotoM, IwaiKet al. The τ protein of oral epithelium increases in Alzheimer’s disease. J. Gerontol. A Biol. Sci. Med. Sci., 57(1), M64–70 (2002).
   PubMed Web of Science ®Google Scholar
• Arredondo LF , Aranda-RomoS, Rodríguez-LeyvaIet al. Tau protein in oral mucosa and cognitive state: a cross-sectional study. Front. Neurol., 8, 554 (2017).
   PubMed Web of Science ®Google Scholar
• Yao F , HongX, LiSet al. Urine based biomarkers for Alzheimer’s disease identified through coupling computational and experimental methods. J. Alzheimers Dis., 65(2), 421–431 (2018).
   PubMed Web of Science ®Google Scholar
• Ma L , ChenJ, WangRet al. The level of Alzheimer-associated neuronal thread protein in urine may be an important biomarker of mild cognitive impairment. J. Clin. Neurosci., 22(4), 649–652 (2015).
   PubMed Web of Science ®Google Scholar
• Lukiw WJ , VergalloA, ListaS, HampelH, ZhaoY. Biomarkers for Alzheimer’s disease (Ad) and the application of precision medicine. J. Pers. Med., 10(3), 138 (2020).
   PubMed Web of Science ®Google Scholar
• Murray ME , Graff-RadfordNR, RossOA, PetersenRC, DuaraR, DicksonDW. Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol., 10(9), 785–796 (2011).
   PubMed Web of Science ®Google Scholar
• Ferreira D , NordbergA, WestmanE. Biological subtypes of Alzheimer disease: a systematic review and meta-analysis. Neurology, 94(10), 436–448 (2020).
   PubMed Web of Science ®Google Scholar
• Vos SJB , VisserPJ, VerheyFet al. Variability of CSF Alzheimer’s disease biomarkers: implications for clinical practice. PLoS ONE, 9(6), e100784 (2014).
   PubMed Web of Science ®Google Scholar
• Mattsson N , ZetterbergH, JanelidzeSet al. Plasma tau in Alzheimer disease. Neurology, 87(17), 1827–1835 (2016).
   PubMed Web of Science ®Google Scholar
• Bolstad N , WarrenDJ, NustadK. Heterophilic antibody interference in immunometric assays. Best Pract. Res. Clin. Endocrinol. Metab., 27(5), 647–661 (2013).
   PubMed Web of Science ®Google Scholar
• Sehlin D , SöllvanderS, PaulieSet al. Interference from heterophilic antibodies in amyloid-β oligomer ELISAs. J. Alzheimers Dis., 21, 1295–1301 (2010).
   PubMed Web of Science ®Google Scholar
• Fink HA , LinskensEJ, SilvermanPCet al. Accuracy of biomarker testing for neuropathologically defined Alzheimer disease in older adults with dementia. Ann. Intern. Med., 172(10), 669–677 (2020).
   PubMed Web of Science ®Google Scholar
• Ferretti MT , IulitaMF, CavedoEet al. Sex differences in Alzheimer disease – the gateway to precision medicine. Nat. Rev. Neurol., 14(8), 457–469 (2018).
   PubMed Web of Science ®Google Scholar
• Sjögren M , VandersticheleH, ÅgrenHet al. Tau and Aβ42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clin. Chem., 47(10), 1776–1781 (2001).
   PubMed Web of Science ®Google Scholar
• Yilmaz A , BlennowK, HagbergLet al. Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev. Mol. Diagn., 17(8), 761–770 (2017).
   PubMed Web of Science ®Google Scholar
• Sørensen K , PelikanJM, RöthlinFet al. Health literacy in Europe: comparative results of the European health literacy survey (HLS-EU). Eur. J. Public Health, 25(6), 1053–1058 (2015).
   PubMed Web of Science ®Google Scholar
• Delaney KP , BransonBM, UniyalAet al. Performance of an oral fluid rapid HIV-1/2 test: experience from four CDC studies. AIDS, 20(12), 1655–1660 (2006).
   PubMed Web of Science ®Google Scholar
• Pantzar A , AttiAR, FratiglioniL, FastbomJ, BäckmanL, LaukkaEJ. Cognitive performance in unipolar old-age depression: a longitudinal study. Int. J. Geriatr. Psychiatry, 32(6), 675–684 (2017).
   PubMed Web of Science ®Google Scholar